Bausch + Lomb Corp
BLCO13.790USD
+0.290+2.15%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.88BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Bausch + Lomb Corp Unternehmen
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Unternehmensinformationen
BörsenkürzelBLCO
Name des UnternehmensBausch + Lomb Corp
IPO-datumMay 06, 2022
CEOMr. Brenton L. (Brent) Saunders, J.D.
Anzahl der mitarbeiter13500
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse520 Applewood Crescent
StadtVAUGHAN
BörseNYSE Consolidated
LandCanada
PostleitzahlL4K 4B4
Telefon19082552864
Websitehttps://ir.bausch.com/
BörsenkürzelBLCO
IPO-datumMay 06, 2022
CEOMr. Brenton L. (Brent) Saunders, J.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Brett M. Icahn
Mr. Brett M. Icahn
Independent Director
Independent Director
75.84K
+85.85%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
71.22K
-2.95%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
50.46K
-5.33%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Karen L. Ling
Ms. Karen L. Ling
Independent Director
Independent Director
--
--
Mr. Gary Hu
Mr. Gary Hu
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Brett M. Icahn
Mr. Brett M. Icahn
Independent Director
Independent Director
75.84K
+85.85%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
71.22K
-2.95%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
50.46K
-5.33%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Devices
448.00M
39.40%
OTC
409.00M
35.97%
Pharmaceuticals
222.00M
19.53%
Branded and other Generics
54.00M
4.75%
Other revenues
4.00M
0.35%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Devices
448.00M
39.40%
OTC
409.00M
35.97%
Pharmaceuticals
222.00M
19.53%
Branded and other Generics
54.00M
4.75%
Other revenues
4.00M
0.35%
Aktionärsstatistik
Aktualisiert: Tue, Jul 29
Aktualisiert: Tue, Jul 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bausch Health Companies Inc
87.75%
Deutsche Bank Securities Inc.
0.99%
Icahn Associates Corporation
0.99%
Alberta Investment Management Corporation
0.92%
GoldenTree Asset Management, LP
0.64%
Other
8.72%
Aktionäre
Aktionäre
Anteil
Bausch Health Companies Inc
87.75%
Deutsche Bank Securities Inc.
0.99%
Icahn Associates Corporation
0.99%
Alberta Investment Management Corporation
0.92%
GoldenTree Asset Management, LP
0.64%
Other
8.72%
Aktionärstypen
Aktionäre
Anteil
Corporation
87.75%
Hedge Fund
4.16%
Investment Advisor/Hedge Fund
2.86%
Research Firm
1.52%
Investment Advisor
1.21%
Sovereign Wealth Fund
0.92%
Individual Investor
0.45%
Pension Fund
0.25%
Family Office
0.18%
Other
0.71%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
263
350.73M
99.13%
-18.03M
2025Q1
273
350.60M
99.12%
-19.40M
2024Q4
262
347.48M
98.58%
-23.77M
2024Q3
257
349.38M
99.14%
-19.72M
2024Q2
260
352.10M
99.92%
-21.43M
2024Q1
247
349.79M
99.91%
-25.18M
2023Q4
237
351.31M
100.35%
-21.66M
2023Q3
219
355.43M
101.52%
-16.80M
2023Q2
207
357.28M
102.06%
-12.23M
2023Q1
194
356.91M
101.97%
-11.11M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bausch Health Companies Inc
310.45M
87.77%
--
--
Mar 24, 2025
Deutsche Bank Securities Inc.
3.50M
0.99%
+3.50M
--
Mar 31, 2025
Icahn Associates Corporation
3.50M
0.99%
--
--
Mar 31, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
GoldenTree Asset Management, LP
2.25M
0.64%
+516.07K
+29.79%
Mar 31, 2025
Maple Rock Capital Partners, Inc.
1.97M
0.56%
-1.20M
-37.84%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.88M
0.53%
-6.18K
-0.33%
Mar 31, 2025
Whitebox Advisors, L.L.C.
1.62M
0.46%
+179.78K
+12.46%
Mar 31, 2025
River Road Asset Management, LLC
1.59M
0.45%
+85.05K
+5.64%
Mar 31, 2025
Arrowstreet Capital, Limited Partnership
1.52M
0.43%
+301.42K
+24.74%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Ballast Small/Mid Cap ETF
1.28%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Invesco RAFI Developed Mkts ex-US SM ETF
0.02%
Schwab Fundamental International Small Equity ETF
0.01%
Fidelity Sustainable High Yield ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
First Trust US Equity Opportunities ETF
0%
Mehr Anzeigen
Ballast Small/Mid Cap ETF
Anteil1.28%
BNY Mellon US Small Cap Core Equity ETF
Anteil0.03%
Invesco RAFI Developed Mkts ex-US SM ETF
Anteil0.02%
Schwab Fundamental International Small Equity ETF
Anteil0.01%
Fidelity Sustainable High Yield ETF
Anteil0%
QRAFT AI-Enhanced US Large Cap ETF
Anteil0%
DFA Dimensional Intl Sustainability Core 1 ETF
Anteil0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Anteil0%
Invesco Zacks Mid-Cap ETF
Anteil0%
First Trust US Equity Opportunities ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
